Salarius Pharmaceuticals with ticker code (SLRX) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 5 and 3.8 with the average target price sitting at 4.43. Given that the stocks previous close was at 0.83 this now indicates there is a potential upside of 433.7%. The 50 day MA is 0.81 and the 200 day MA is 1.03. The company has a market capitalisation of $16m. Find out more information at: http://www.salariuspharma.com
Salarius Pharmaceuticals a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company’s lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.